Low-dose aspirin as effective as higher dose after percutaneous coronary intervention - and safer

摘要

Patients with acute coronary syndromes (ACS)undergoing percutaneous coronary intervention (PCI)experience similarly low rates of cardiovascular events with low-dose aspirin as those treated with higher doses,but with less risk of major bleeding,according to results from a major study.A sub-analysis of the PCI-CURE study compared the safety and efficacy of low (<100mg),intermediate (101-199mg).and high (>200mg)doses of aspirin in 2,658 patients with ACS undergoing PCI.Data presented earlier this week at the American College of Cardiology 56th Annual Scientific Session,held in New Orleans,Louisiana,reveal similar rates of cardiovascular death,myocardial infarction or stroke in all of the aspirin dose groups at 30 days and at eight months (4.1 per cent with <100mg aspirin versus 4.0 per cent with >200mg at 30 days).